Showing 5601-5610 of 6035 results for "".
- Notal Vision Diagnostic Clinic Reports Completion of 6 Million ForeseeHome AMD Home-Monitoring Testshttps://modernod.com/news/notal-vision-diagnostic-clinic-reports-completion-of-6-million-foreseehome-amd-home-monitoring-tests/2476750/Notal Vision announced the completion of 6 million patient tests performed with ForeseeHome, the first FDA-cleared home-monitoring device for patients with intermediate dry age-related macular degeneration (AMD) at risk for developing wet AMD, according to a company news release. ForeseeHo
- Nidek Launches LPM Low Power Mode for YLC-500 Vixihttps://modernod.com/news/nidek-launches-lpm-low-power-mode-for-ylc-500-vixi/2476744/Nidek has announced the launch of LPM optional software, a low power mode for the YLC-500 Vixi laser photocoagulator. LPM delivers a therapeutic effect to the retina by decreasing the laser power during photocoagulati
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- FDA Does Not Approve Bausch Health, Eton’s Pharma’s EM-100 for Allergic Conjunctivitishttps://modernod.com/news/fda-does-not-approve-bausch-health-etons-pharmas-em-100-for-allergic-conjunctivitis/2476731/Eton Pharmaceuticals on Friday said that partner Bausch Health Companies has received a complete response letter from the FDA for its filing seeking approval of the investigational therapy EM-100 to treat ocular itching associated with allergic conjunctivitis. “We
- US Scraps Proposal to Curb Drug Rebates Paid to Pharmacy Benefit Managershttps://modernod.com/news/us-scraps-proposal-to-curb-drug-rebates-paid-to-pharmacy-benefit-managers/2476729/The US government pulled the plug on plans designed to reduce drug prices by limiting rebates paid by drugmakers to pharmacy benefit managers (PBMs). White House spokesman Judd Deere said on Thursday that “based on careful analysis and thorough consideration, the President has decided to wi
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- Prevent Blindness Focus On Eye Health National Summithttps://modernod.com/news/prevent-blindness-focus-on-eye-health-national-summit/2476719/Prevent Blindness will host the 8th Annual Focus on Eye Health National Summit at the National Press Club in Washington DC on Wednesday, July 17 at 7:30 am ET. The theme of the event is “A Lifetime of Vision” and will feature keynote speaker Bill Barkley, deaf-blind adventure
- Horizon Therapeutics Submits Biologics License Application for the Treatment of Active Thyroid Eye Diseasehttps://modernod.com/news/horizon-therapeutics-submits-biologics-license-application-for-the-treatment-of-active-thyroid-eye-disease/2476716/Horizon Therapeutics announced that it has submitted a biologics license application (BLA) to the FDA for its investigational medicine teprotumumab for the treatment of active thyroid eye disease (TED). Teprotumumab has breakthrough therapy, orphan drug and fast track designations from the FDA. H
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- Bausch + Lomb Announces US Launch Of Ocuvite Eye Performance Vitaminshttps://modernod.com/news/bausch-lomb-announces-us-launch-of-ocuvite-eye-performance-vitamins/2476714/Bausch + Lomb announced the US launch of Ocuvite Eye Performance vitamins, which were formulated with seven nutrients that help strengthen the macula. The nutrients protect the eye from stressors such as sun light and blue light emitted from digital devices. These nutrients include lutein